Muscarinic receptor antagonists
AssigneePfizer Inc.
InventorsPeter E. Cross, Alexander R. MacKenzie
Life of this patent
Estimating the term…
Abstract
Compounds of the formula I ##STR1## wherein X, Y and v are as defined below, novel intermediates used in their synthesis, and the pharmaceutically acceptable salts of such compounds and intermediates. The compounds of formula I and the novel intermediates used in their synthesis are muscarinic receptor antagonists that are selected for smooth muscle muscarinic sites and are useful in the prevention and treatment of diseases associated with altered motility or tone of smooth muscle, such as irritable bowel syndrome, diverticular disease, urinary incontinence, aesophageal achalasia, and chronic obstructive airways disease.
Claims1
A method of treating a disease associated with the altered motility or tone of smooth muscle in a mammal, comprising administering to said mammal an amount of a compound according to the formula ##STR75## or pharmaceutically acceptable salt thereof, wherein v is 0 or 1, and when v is 0, there is no bond between the carbons at positions a and b;
- Y is --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --CH.sub.2 --S--, --CH.sub.2 --O--, --O-- or --S--;
- and X is a group of the formula:
- ##STR76## wherein m is 1 or 2;
- R.sup.1 and R.sup.2 are each independently H or (C.sub.1 -C.sub.4)alkyl, or R.sup.1 and R.sup.2 together represent --(CH.sub.2).sub.n -- wherein n is an integer of from 2 to 5;
- R.sup.3 is H or (C.sub.1 -C.sub.4)alkyl;
- Z is a direct link, --CH.sub.2 --, --(CH.sub.2).sub.2 --, --CH.sub.2 O-- or --CH.sub.2 S--;
- and
- R.sup.4 is pyridyl, pyrazinyl, thienyl or a group of the formula ##STR77## wherein either R.sup.5 and R.sup.6 are each independently selected from H, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, halo, --CF.sub.3, --CN, --(CH.sub.2).sub.p NR.sup.7 R.sup.8, --OCO(C.sub.1 -C.sub.4)alkyl, --CO(C.sub.1 -C.sub.4)alkyl, --CH(OH)(C.sub.1 -C.sub.4)alkyl, --C(OH)--di(C.sub.1 -C.sub.4)alkyl, --SO.sub.2 NH.sub.2, --NHSO.sub.2 (C.sub.1 -C.sub.4)alkyl, --(CH.sub.2).sub.p OH, --(CH.sub.2).sub.p COO(C.sub.1 -C.sub.4)alkyl and, (CH.sub.2).sub.p CONR.sup.7 R.sup.8, or R.sup.5 and R.sup.6 together represent --(CH.sub.2).sub.q --, --O(CH.sub.2).sub.r O-- wherein one oxygen atom is attached to the 3-position of the benzene ring and the other is attached to the 4-position, or --O(CH.sub.2).sub.t -- wherein the oxygen atom is attached to the 3- or 4-position of the benzene ring;
- R.sup.7 and R.sup.8 are each independently 8 or (C.sub.1 -C.sub.4)alkyl;
- p is 0, 1 or 2;
- q is 3, 4 or 5;
- r is 1, 2 or 3;
- and
- t is 2, 3 or 4;
- effective in alleviating such disease.
Dependencies are inferred from the claim text.